atai Life Sciences to Announce First-Quarter 2022 Financial Results
04 May 2022 - 06:00PM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, will announce its first-quarter 2022
financial results by posting them on the IR portion of its website.
Please visit the atai investor relations website at
https://ir.atai.life to view Q1’22 financial results and press
release.
A video interview with atai Life Sciences CEO Florian
Brand, CSO Srinivas Rao, and CFO Greg Weaver will be available
at 8:30 A.M. Eastern Time at https://vimeo.com/atailifesciences.
Questions that investors would like to see asked should be sent to
ir@atai.life by Monday, May 9, 2022.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to
transform the treatment of mental health disorders. atai was
founded in 2018 as a response to the significant unmet need and
lack of innovation in the mental health treatment landscape. atai
is dedicated to acquiring, incubating and efficiently developing
innovative therapeutics to treat depression, anxiety, addiction,
and other mental health disorders.
atai's business model combines funding, technology, scientific
and regulatory expertise with a focus on psychedelic therapy and
other drugs with differentiated safety profiles and therapeutic
potential. By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies, seeking to effectively treat and ultimately heal mental
health disorders.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. atai has
offices in New York, Boston, London, and Berlin. For more
information, please visit www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including without limitation
statements regarding atai’s participation in upcoming conferences
and presentations and similar statements of a future or
forward-looking nature. Forward-looking statements are neither
promises nor guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially
from those projected, including, without limitation, the important
factors discussed under the caption “Risk Factors” in atai's
prospectus pursuant to Rule 424(b) filed with the U.S. Securities
and Exchange Commission (“SEC”) on June 21, 2021, as such factors
may be updated from time to time in atai's other filings with the
SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof and accordingly undue reliance
should not be placed on such statements. atai disclaims any
obligation or undertaking to update or revise any forward-looking
statements contained in this press release, whether as a result of
new information, future events or otherwise, other than to the
extent required by applicable law.
Contact Information
Investor Contact:Greg WeaverChief Financial
OfficerEmail: greg.weaver@atai.life
Media Contact:Maggie Gordon Senior Manager,
CommunicationsEmail: maggie@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Feb 2024 to Mar 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Mar 2023 to Mar 2024